The pharmacokinetics and pharmacodynamics of mycophenolic acid differ significantly between patients, and these differences are affected by a variety of factors such as gender, body weight, ethnicity, albumin level, hepatic and renal function, post-transplantation time, and genetic polymorphisms. Studies have shown ^[3] that when administered at a fixed dose, the trough concentration of mycophenolic acid (C₀) can vary up to 10-fold and the AUC_0-12 can vary up to 5-fold between patients, while the area under the curve at the time of administration (AUC_0-12 ) is significantly correlated with the immunosuppressive efficacy of mycophenolic acid and the toxic side-effects，which shows that there is a large individual variability in the level of mycophenolic acid exposure in vivo. Therefore, individualized administration of mycophenolic acid in combination with therapeutic drug monitoring (TDM) is required in clinical applications.

Transplant centers at home and abroad recommend that MPA AUC_0-12h be controlled within 30-60 mg.h^-1.L^-1 , and this therapeutic window range is recommended to be graded as (B, II) in the newly published consensus report on individualized treatment of MPA^[3] . Mycophenolic acid blood levels were significantly correlated with immunosuppressive efficacy and toxic side effects. When AUC_0-12h <30mg.h^-1.L^-1 , there is an increased probability of acute rejection, while AUC_0-12h >60mg.h^-1.L^-1 is susceptible to adverse reactions such as leukopenia, anemia, and increased risk of infection^[5] . Therefore, blood concentration testing of MPA is of great significance to improve its clinical efficacy and reduce the incidence of adverse reactions.

Through mycophenolic acid therapeutic drug monitoring (TDM), the dose of mycophenolate mofetil (MMF) can be rationally adjusted, so that the MPA-AUC_0-12h reaches 30~60 mg.h^-1.L^-1[3]. By monitoring the blood concentration of MPA, doctors can adjust the treatment program in time in order to achieve optimal therapeutic efficacy and minimize the side effects, especially in the transplantation stabilization period using a low-dose or withdrawal of calcineurin phosphatase inhibitors (e.g., cyclosporine A and tacrolimus) or corticosteroids in the regimen, by monitoring MPA thereby safely and effectively reducing the dosage of corticosteroids.

Studies have shown significant associations between free mycophenolic acid (fMPA) concentrations and hematologic adverse effects, including leukopenia and thrombocytopenia, with a negative correlation between the free MPA fraction and leukocyte counts ^[4]. Albumin levels were significantly positively correlated with MPA exposure, whereas leukocyte levels were significantly negatively correlated with it. This implies that changes in albumin levels can be used as a reference factor for adjusting MPA dosage to minimize the incidence of hematologic adverse reactions. The cut-off values of MPA AUC for predicting under-exposure to MPA and leukopenia were 126.3 mg.h^-1.L^-1, respectively. This suggests that by monitoring the AUC of MPA, it is possible to predict the risk of hematologic adverse reactions and to adjust the therapeutic regimen accordingly ^[5] .